Innovative Liquid Biopsy Epic Sciences specializes in non-invasive diagnostics for cancer, providing technologies like circulating tumor cell analysis and liquid biopsies, which are highly valuable for hospitals, clinics, and pharmaceutical companies seeking to improve personalized cancer treatment monitoring.

Strong Funding Growth Recent Series G funding of $24 million and a previous $43 million Series F investment indicate robust financial backing, demonstrating confidence from investors such as Arsenal Capital Partners and Deerfield Management, which underscores the company's potential for market expansion and product adoption.

Strategic Partnerships Epic’s collaborations with leading pharmaceutical firms and major cancer centers worldwide suggest opportunities for sales dialogue around integrated diagnostics, clinical trial support, and tailored treatment solutions, broadening the company's influence in the oncology market.

Product Expansion Launch of defineMBC, a blood test for metastatic breast cancer, shows Epic’s commitment to expanding its diagnostic portfolio, creating potential opportunities to cross-sell or introduce new tests to oncology and diagnostic service providers.

Market Positioning Operating within the competitive liquid biopsy and cancer diagnostics space alongside companies like Guardant Health and Foundation Medicine, Epic’s advanced cellular analysis platform can be positioned as a high-value solution for biotech and healthcare providers aiming to enhance real-time treatment decisions.